Upload Avatar (500 x 500)
Wenbing Dai
Pharmaceutical Sciences
Peking University
Beijing
Language: Chinese, English
Peptide
Self-Assembly
Drug Delivery
Antibody
Nanomedicine
Translational Research
Cancer Therapy
Nanotechnology
Pharmaceutical Sciences
Biomedical Engineering
Areas of Focus
- Peptide-based self-assembly drug delivery
- Antibody drug delivery
- New strategies and translational research for drug nanonization
Work Experience
- 2018.08 - Present: Peking University School of Pharmaceutical Sciences - Associate Professor
- 2017.09 - 2018.10: Johns Hopkins University - Visiting Scholar
- 2012.08 - 2018.07: Peking University School of Pharmaceutical Sciences - Assistant Researcher
Academic Background & Achievements
- 2006.09-2009.07 PhD: Peking University School of Pharmaceutical Sciences
- 2003.09-2006.07 Master's: Wuhan University School of Pharmaceutical Sciences
- 1999.09-2003.07 Bachelor's: Wuhan University School of Pharmaceutical Sciences
- H-index of 36
- Obtained clinical approvals for 2 improved new drugs
- Received 1 National Science and Technology Progress Award (Second Prize)
- Received 1 Ministry of Education Natural Science Award (First Prize)
Publications
- An enzyme-responsive and transformable PD-L1 blocking peptide-photosensitizer conjugate enables efficient photothermal immunotherapy for breast cancer, Yanan Sun, Bochen Lyu, Chang Yang, Bing He, Hua Zhang, Xueqing Wang, Qiang Zhang, Wenbing Dai, 2023
- Strengthened Tumor Photodynamic Therapy Based on a Visible Nanoscale Covalent Organic Polymer Engineered by Microwave Assisted Synthesis, Yao Lu, Ge Song, Bing He, Hua Zhang, Xueqing Wang, Demin Zhou, Wenbing Dai, Qiang Zhang, 2020
- A combined “eat me/don’t eat me” strategy based on extracellular vesicles for anticancer nanomedicines, Zakia Belhadj, Bing He, Hailiang Deng, Siyang Song, Hua Zhang, Xueqing Wang, Wenbing Dai, Qiang Zhang, 2020
- Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system, Binlong Chen, Wenbing Dai, Dong Mei, Tongzhou Liu, Suxin Li, Bo He, Bing He, Lan Yuan, Hua Zhang, Xueqing Wang, Qiang Zhang, 2016
- Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer, Wenbing Dai, Fang Yang, Ling Ma, Yuchen Fan, Bing He, Qihua He, Xueqing Wang, Hua Zhang, Qiang Zhang, 2014
Awards
- National Science and Technology Progress Award (Second Prize): Detail
- Ministry of Education Natural Science Award (First Prize): Detail
